In-hospital death risk in Russian patients with STEMI
Introduction
The study of risk factors among patients with acute coronary syndrome (ACS) is an important problem of contemporary cardiology. Many studies are devoted to this problem [1-4, etc.] . Different algorithms have been proposed for estimating the risk of death after ACS (GRACE, TIMI) [5, 6] . In the most known algorithms, all factors determining the probability of death in patients with ACS are patient-related, e.g. age, sex, history of cardiovascular diseases (CVD), family history of coronary artery disease (CAD) and premature death, and clinical status at admission. To optimize treatment it is important to study the impact of treatment-related factors (hospital drug treatment and timeliness of reperfusion) on the patient risk.
Recently, much attention is paid to the study of risk factors in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) [7,8, etc.] . It is well known that the quality of reperfusion therapy is a risk factor of a short-term mortality in patients with STEMI patients [9, 10] . The American College of Cardiology and the American Heart Association have published in 2008 the task force on performance measures for STEMI and non-STEMI [11] . Clinical measures (Time to fi brinolytic therapy, Time to PCI and Reperfusion therapy) have been designed to assess the quality of primary reperfusion therapy in patients with STEMI.
In the present retrospective study we examined relationships between different patient-related factors (patient's clinical characteristics), treatment-related factors (hospital drug treatment and reperfusion therapy and its performance) and in-hospital mortality among Russian patients with STEMI.
Material and methods

Data source
The Registry of Acute Coronary Syndrome of the Ministry of Health of Russian Federation (hereafter referred as Russian ACS Registry) was used as a source of data about ACS patients [12] . It is a retrospective, continuous, nationwide, Web-based registry operating on-line. Participation in the Russian ACS Registry is voluntary. The access to the registry is given only to registered members.
The Registry database was developed using ACCF/ AHA 2011 Key data elements and defi nitions of a base cardiovascular vocabulary for electronic health records [13] . Data on clinical characteristics, prior, hospital drug treatment and reperfusion therapy was collected. Data on post-hospital treatment of ACS patients was not included in the Russian ACS Registry database. The source of patients' data was a hospital chart.
Centers participating in the Russian ACS Registry are asked to include continuously all patients following inclusion/exclusion criteria who were treated from ACS during the year prior to the year of participation. Russian ACS Registry inclusion criteria [14] are the following:
(i) age ≥ 18 years; (ii) any type of ACS as a presumptive diagnosis; (iii) patient's hospital chart is fi nished; (iv) absence of any exclusion criteria. Russian ACS Registry exclusion criteria [14] are the following:
(i) symptoms considered as consistent with acute cardiac ischemia are absent within the last 24 hours prior to admission; (ii) patient was transferred into a registry hospital in more than 24 hours after admission to the initial hospital; (iii) patient was transferred out of a registry hospital in less than 24 hours after admission; (iv) ACS symptoms occurred after hospitalization at other reasons; (v) ACS is accompanied by a signifi cant co-morbidity such as a motor vehicle accident, trauma, severe gastrointestinal bleeding, operation or procedure directly before admission.
Patient selection
Retrospective data on clinical characteristics, prior and hospital drug treatment, reperfusion therapy and in-hospital mortality contained in the 2010-2011 Russian ACS Registry from 25,682 patients with STEMI were examined. The average age of patients was 63 (55-74) years. 34% of patients were female. These patients were treated in 155 cardiological units located in 46 regions of Russia. Death was defi ned as endpoint of study. Duration of hospital treatment was from 9 to 21 days for survived patients. Mortality rate was 8.1%. Most defi nitions of clinical data in the Russian ACS Registry are consistent with W.S. Weintraub et al. [13] . We used the following criteria to select patients for the study: (i) diagnosis of STEMI (data from the Russian ACS Registry), (ii) age between 18 and 80 years. The patients were excluded from the study if they ha d missing data on the time of reperfusion (time of fi brinolytic agent injection and/or time of balloon infl ation during PCI), hospital presentation and treatment.
The patients over 80 years were not included in the present study because of proven disparities in treatment of ACS in the elderly and younger subjects [15] [16] [17] . It was 
Statistical analysis
We applied the Shapiro-Wilk test to check whether the data were approximately normally distributed. Since some data occurred to be non-normal, their further analysis was carried out using non-parametric statistical methods. We applied the Chi-square ( 2 ) test to compare the binary variables and to compute the signifi cance level for the difference between two proportions. Mann-Whitney test was used to compare the continuous variables. Categorical data are presented as frequencies and percentages. Continuous variables are reported as mean, medians (Me) with standard deviations (SD) and inter-quartile ranges (Q1, Q3).
Cox's proportional hazard models were used for multivariate analysis of dependence between fatal cardiovascular event (death) and various factors (patient-related and treatment-related) during inpatient admission (in hours). We selected the factors for multivariate analysis basing on the results of univariate comparison between deceased patients and survived patients (p < 0.05 in Table 2 ).
In our study the risk index Exp(B) estimates the hazard ratio of in-hospital mortality. The risk index Exp(B) is the ratio of hazards between two individuals whose values of x 1 differ by one unit while all other covariates are held constant. In Cox regression the hazard function is modeled as h(t) = h 0 (t)exp( x), where h 0 (t) is the baseline hazard, which cannot be estimated. In spite of this, one can estimate . If = 0, then the hazard ratio for this covariate is equal to Exp 0 = 1, i.e., this covariate does not affect survival.
The obtained estimations were considered statistically signifi cant if p < 0.05. For the statistical analysis, the software package Statistica 6.1 (Statsoft Inc., USA) was used.
Results
Characteristics of the registry population with STEMI
Clinical characteristics of enrolled patients with STEMI are presented in Table 2 . Total rate of death in hospital was 8.1%. Survival plot is shown in Figure 1 . Clinical characteristics of deceased patients and survived patients are shown separately.
previously reported that high age itself is a predominant clinical factor infl uencing on implementation of recommended (especially invasive) treatment among aged patients in Russia in spite of their higher risk of in-hospital death [18, 19] . This limitation of the present study is indicated in the Limitation section.
Patient-related and treatment-related factors in patients with STEMI
All clinical factors, which could not be changed by medical care of present event, were named as patient-related factors. Other factors, which could be modifi ed by treatment, were named as treatment-related factors.
Patient-related factors included age, sex, body mass index (BMI), smoking, prior myocardial infarction (MI), history of stable angina pectoris, prior PCI, family history of premature heart disease (PHD), history of chronic heart failure (CHF), prior stroke, history of peripheral vascular disease (PVD), history of chronic renal insuffi ciency (CRI), history of chronic lung disease (CLD), history of arterial hypertension (AH), diabetes, acute heart failure (AHF) Killip 1-4 at admission, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), pathologic Q wave on electrocardiogram (ECG), right ventricle (RV) dilatation, acute left ventricle (LV) aneurism, thrombus into LV, prior treatment with aspirin, clopidogrel, nitrates, angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin receptors blockers (ARBs), betablockers, dihydropyridine calcium antagonists (DCA), non--dihydropyridine calcium antagonists (NDCA) and statins.
Treatment-related factors included hospital treatment with aspirin, clopidogrel, nitrates, heparin, fondaparinux, ACE-Is or ARBs, beta-blockers, DCA, NDCA, statins, the fact of any reperfusion and timeliness of reperfusion.
One of the factors considered in the analysis was LV ejection fraction (LVEF). LVEF was regarded as combined patient-and treatment-related factor. In Russian STEMI patients LVEF is measured later during the hospital stay. Thus, contractile dysfunction due to infracted myocardium (patient-related component) is compensated by myocardium salvage and recovery of function due to timely treatment (treatment-related component).
Defi nitions of all clinical factors are shown in Table 1 .
Performance measures for reperfusion
Reperfusion therapy was estimated basing on the following performance measures powered by American College of Cardiology and American Heart Association (ACC/AHA) in 2008 year [11] : (i) No. 7 -Time to fi brinolytic therapy, which determines the part of patients with STEMI whose time from hospital admission to fi brinolytic therapy is 30 minutes or less, ii) No. 8 -Time to PCI, which determines the part of patients with STEMI whose time from hospital admission to primary PCI is 90 minutes or less, iii) No. 9 -Reperfusion therapy, which determines the part of patients with STEMI who receive any reperfusion treatment within 12 hours of symptom onset.
ACC/AHA performance measures were estimated in those STEMI patients who met the measure inclusion and exclusion criteria [11] . The average age of enrolled patients was 63 (55-74) years. 34% of patients were female. 29.9% of patients were admitted to hospital with acute heart failure and 36.6% of patients admitted with pathological Q-wave on electrocardiogram. More than half of all patients with STEMI had the left ventricle systolic dysfunction (ejection fraction is less than 49%). Survived patients differed signifi cantly from deceased patients in the majority of demographics, anamnesis, clinical presentation and treatment parameters (Table 2) . 20 .8% of all patients with STEMI followed PCI (18.5% during the fi rst day and 2.3% later than 24 hours after admission). 29.3% of all STEMI patients received fi brinolisys and 0.4% of patients received coronary artery bypass graft (CABG) during the fi rst 24 hours after admission.
Selection of patients for carrying out ACC/AHA measures showed the following results. ACC/AHA measure "Time to fi brinolysis" could be estimated for 5,119 STEMI patients (19.9% of general group of 25,682 patients). ACC/ AHA measure "Time to PCI" could be estimated for 3,993 Assessment of the quality of reperfusion with the help of ACC/AHA measures (see the section Performance measures for reperfusion) showed the following results. In 65.3% of applicable STEMI patients (3,343 from 5,119 patients) the time from hospital arrival to fi brinolytic therapy was 30 minutes or less (ACC/AHA measure No. 7 "Time to fi brinolisys"). In 70.0% of applicable STEMI patients (2,795 from 3,993 patients) the time from hospital arrival to primary PCI was 90 minutes or less (ACC/ AHA measure No. 8 "Time to PCI"). 81.4% of applicable STEMI patients (9,803 from 12,043 patients) received fi brinolytic therapy or primary PCI (ACC/AHA measure No. 9 "Reperfusion therapy"). It is important that obtained results of ACC/AHA measures were derived from the data of applicable STEMI patients. The proportions of STEMI patients who met ACC/AHA measures differed signifi cantly on conversion to the general group of patients. ACC/AHA measure No. 7 "Time to fi brinolysis" was fulfi lled in 13.0% of all STEMI patients enrolled in the study (3,343 from 25,682 patients). 10.9% (2,795 from 25,682 patients) and 38.2% (9,803 from 25,682 patients) of all studied STEMI patients met ACC/AHA measure No. 8 "Time to PCI" and ACC/AHA measure No. 9 "Reperfusion therapy", respectively.
Effect of treatment-and patient-related factors on survival in patients with STEMI
We evaluated a relationship between all patient-and treatment-related factors and the risk of in-hospital mortality from any cardiovascular event in the general group of patients with STEMI using multivariable Cox's regression model. This model gives 2 = 482.1 (p < 0.0001). The values of the main clinical characteristics in the model are summarized in Table  3 . Statistically signifi cant parameters have p-level less than 0.05 (these 15 factors are marked with bold type in Table 3 ).
The regression coeffi cient b for these factors indicates that the risk of in-hospital mortality in patients with STEMI increases with the increase of age, heart rate, acute heart failure Killip, blood glucose and right ventricular dilatation and with the presence of pathological Q-wave on ECG and acute left ventricular aneurism. The risk increases with the decrease of left ventricular ejection fraction, diastolic blood pressure and triglycerides and with the lack of hospital treatment by angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), -blockers and statins. Prognostic value of other clinical factors, including any reperfusion therapy and measures of its timeliness, exploited the assessment of risk of in-hospital mortality using Cox's regression models was not statistically significant (p ≥ 0.05 for Wald test for each factor) ( Table 3) .
Since short duration of stay in hospital may hamper performance of recommended treatment interventions and consequently distort the extent of their infl uence on in-hospital mortality, we compared clinical characteristics and treatment of STEMI patients who have died during the fi rst 24 hours after admission (n = 125; 6.0% of all deceased pts.) and later on (n = 1,955; 94.0% of all deceased pts.). Statistically signifi cant difference between the selected subgr oups was observed just in administration of ACE-Is/ARBs (30.4% vs 45.5%, respectively, p = 0.024). The subgroups were comparable with respect to other clinical and treatment parameters. In patients who have died during the fi rst 24 hours after admission, ACE-Is or ARBs were administered rarely in comparison with the patients who have deceased later. But it was not associated with the severity of their clinical status. Thus, the degree of ACE-Is and ARBs infl uence on the fi rst-day mortality needs further research. As for in-hospital mortality in general, the Cox's regression model used for the analysis took into account the time (in hours) from hospital admission to death in order to assess the infl uence of treatment-related factors on patient.
Discussion
In our study we examined the impact of guideline-recommended inpatient interventions on in-hospital mortality of patients with STEMI using the data of Russian Acute Coronary Syndrome Registry. It is shown that (1) the lack of in-hospital treatment with ACE-Is, ARBs, -blockers and statins is the major treatment-related factor related signifi cantly with the increased risk of death in hospital; (2) the performance of reperfusion therapy is not the leading factor infl uencing on in-hospital mortality; (3) the present-day completeness of data obtained retrospectively from patients' medical records is defi cient for estimating ACC/AHA measures of reperfusion quality (ACC/AHA measures "Time to fi brinolysis", "Time to PCI" and "Reperfusion therapy" were estimated for 19.9%, 15.5% and 46.9% of patients, respectively, from general group). The obtained results allowed us to reveal the most important treatment interventions. They showed the care gaps and gave the opportunities to upgrade the national STEMI performance measurement set.
We have found only one similar study in literature, which investigates relationship between hospital process performance and outcomes in patients with non-ST elevation acute coronary syndrome [20, 21] . This study has shown that guidelines adherence and in-hospital mortality correlate signifi cantly.
In the present study we tried to analyze the factors infl uencing on the risk of death in hospital after STEMI with respect to its modifi ability by treatment. It is important to know the impact of treatment-related factors to the risk of death in order to concentrate medical care efforts on such factors.
It is already known that the majority of factors contributing to in-hospital mortality from MI and STEMI are associated in particular with patient clinical status at admission and cannot be modifi ed by hospital treatment. These factors are age [5, 6, [22] [23] [24] [25] [26] [27] , ST-segment deviation [5, 6] , AH [6, 28] , smoking [6, 28] , family history of PHD [6] , prior stroke, untreated dyslipidaemia [6, 23] , diabetes [6, 23] , low SBP (up to hypotension, which is associated with the increasing Killip class of AHF) [5, 6] , Killip class (up to cardiogenic shock) [5, 22, 25, 29] , cardiac arrest at presentation [5] , LVEF (up to congestive heart failure) [27] , elevated cardiac markers [5, 6] , HR [5, 24, 25] , prior treatment with aspirin, known CAD (stenosis ≥ 50%) and severe angina (≥ 2 episodes within 24 hours) [6] .
In our study we confi rmed the importance of the majority of above-mentioned patient-related factors. Some of these factors were qualifi ed as the main ones and the other as additional. We have identifi ed the following main patient-related factors of in-hospital mortality: male sex (some studies obtained the opposite result [30, 31] ), acute LV aneurism, pathological Q-wave on ECG, blood glucose level, triglyceride level and RV dilatation. In-hospital mortality of STEMI patients was not associated with the history of AH. We also showed that DBP had more impact on in-hospital mortality risk in patients with STEMI than SBP. As for TIMI study [6] , only the age was fully consistent with our results on major patient-related risk factors.
Comprehensive information on impact of treatment--related factors on in-hospital mortality in patients with STEMI was absent in literature. We have shown that hospital treatment with ACE-Is, ARBs, -blockers and statins are the main treatment-related factors of in-hospital mortality. Among the set of all signifi cant predictors of in-hospital mortality these medications were the most modifi able factors infl uencing the risk of death. The fi rst additional treatment-related predictor of in-hospital mortality in our study was hospital treatment with aspirin. It is of interest that C.P. Gale et al. considered aspirin and out-of-hospital thrombolysis as the strongest predictors of in-hospital survival in patients with STEMI [24] .
The key point in treatment of STEMI is reperfusion [32, 33] . Prompt reperfusion for all eligible patients with STEMI is a present-day challenge for healthcare. In context of present research, the performance of reperfusion evaluated in terms of ACC/AHA measures was one of treatment-related factors infl uencing on the risk of death in hospital after STEMI. S.M. Gharacholou et al. [34] have previously shown that the absence of timely performed reperfusion is associated with greater in-hospital mortality in patients with STEMI without contraindications. The results of our study in Russian patients with STEMI suggest that reperfusion may reduce short-term mortality risk, if it is performed additionally to basic treatment with main drugs such as ACE-Is, ARBs, -blockers and statins, which are the main predictors of in-hospital mortality. In [35] it was shown that the mortality benefi ts from primary PCI and the hazard of primary PCI-related delay depend on baseline risk due to patients-related factors.
Previously, it was found out that the absolute reduction of the risk of mortality from fi brinolytic therapy or primary PCI depends on the patient baseline risk [36] . Our results confi rmed this conclusion.
For patients with STEMI treated with primary PCI, it is known that renal insuffi ciency is an independent predictor of in-hospital mortality [37, 38] . The results of the present study did not confi rm it.
X.H. Shao et al. [39] have shown that differences in therapeutic approach infl uenced on thirty-day mortality from any reason in STEMI patients. The authors have also revealed gender-related differences in therapeutic approaches. Reperfusion therapy was more often applied to male patients than female ones. As the result, female patients had worse prognosis than male patients. According to [39] , the frequency of -blockers, ACE-Is, statins and other drugs administration in Chinese patients with STEMI was signifi cantly higher in men than in women. Similar gender differences in mortality due to differences in treatment in patients with STEMI were reported by some other authors [40] [41] [42] [43] . According to their results, reperfusion therapy gave the main impact on mortality.
In STEMI population with small in-hospital mortality rate (1.9%) [44] , evidence-based medications (aspirin, statins, -blockers, etc.) were prescribed to the majority of enrolled patients during hospitalization. It was shown in [45] that evidence-based treatments with both reperfusion (fi brinolytic reperfusion or primary PCI) and drug (aspirin, -blockers, statins, ACE-Is, etc.) decrease in-hospital mortality in patients with STEMI from 12.5% to 7.2%. Similar value of evidence-based drug administration was shown in [46, 47] . The results of our study revealed greater infl uence of some drugs prescription on in-hospital mortality than early reperfusion. But it is unquestionable that the performance of reperfusion is the major factor infl uencing on long-term survival of patients with STEMI [32, 33] .
It is obvious that all above mentioned risk predictors are important for short-term prognosis of patients with STEMI and should be taken into account during patients' hospital stay, especially treatment-related factors. In our study we examined the peculiarities of in-hospital mortality predictors in Russian patients with STEMI.
Study limitations
The results have been derived from selected population of Russian ACS patients included in the Russian ACS Registry. Thus, the results extrapolation to the ACS patients from other countries is limited.
Various external factors (non-clinical factors, cancer, anemia, dementia, prior non-cardiac surgery, etc.) that were not taken into account may impact on the results of our study. We can not account for all such factors, especially unmeasured characteristics.
Since the patients with STEMI who have died were older and often had a history of prior MI, diabetes, congestive heart failure, prior stroke and higher prevalence of AHF Killip class > 1 (Table 2 ), the higher mortality in patients not receiving these drugs could partially be the result of severity of illness.
The results of the study were derived from the data on ACS patients included in the Russian ACS Registry with voluntary participation. Since participation in the Russian ACS Registry was voluntary, the centers, which participated in it could be highly equipped and highly motivated willing to expose their practice to criticism. It is probable that these centers more often adhere to guidelines. Thus, extrapolation of results to ACS patients of the whole country, as well as from other countries is limited.
We did not include subjects older than 80 years in this study. The reasons to exclude them are indicated in the Methods section. Exclusion of all patients over 80 years limits the extrapolation of the results.
In the present study, the date and/or the time of several fi ndings and interventions were not considered (see the Data source section). It was caused by the absence of corresponding information in the Russian ACS Registry database. Missing such data may infl uence the results of the study.
We revealed the statistically signifi cant differences in administration of ACE-Is/ARBs in STEMI patients who have died during the fi rst 24 hours after admission and later. These differences were not determined by the patient clinical status. The extent of their infl uence on the total in-hospital mortality needs further investigation.
Conclusion
The majority of leading predictors of in-hospital death in Russian STEMI patients was associated with the patient clinical status at hospital presentation and can not be modifi ed by treatment. The treatment with ACE-Is or ARBs, -blockers and statins during the hospital stay (not necessarily at arrival) infl uenced the risk of death in hospital as strong as the clinical status of patient at admission. The results of our study assume that these inpatient interventions should be carefully controlled and improved to reduce in-hospital mortality from STEMI. It is also shown that reperfusion and its quality are additional factors, which infl uence indirectly on the risk of death in hospital in Russian patients with STEMI.
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